To include your compound in the COVID-19 Resource Center, submit it here.

Daily Chart: Inovio joins COVID-19 vaccine developers showing mouse immunogenicity data

BioCentury is providing this content for free given the urgent need for information about the coronavirus crisis. Further analysis can be found in our COVID-19 Resource Center. For more, sign up for our daily email.

Inovio reported mouse immunogenicity data from its COVID-19 vaccine that include lung detection of anti-SARS-CoV-2 antibodies, hinting at protectiveness. While direct comparison to mouse data from other COVID-19 vaccines is difficult, the findings put the Inovio vaccine roughly on par with University of Oxford’s.

Inovio Pharmaceuticals Inc. (NASDAQ:INO), which gained $1.23 to $15.79 Wednesday, reported in Nature Communications that a single administration of INO-4800 induced serum anti-spike antibody titers of about 2,000 in mice. Two immunizations resulted in serum neutralizing titers of 128.

In guinea pigs, a single immunization -- at a dose four times that given to mice -- led to total serum titers of 10,530, and three vaccinations induced neutralizing titers >320.

Bronchoalveolar lavage fluid from vaccinated mice and guinea pigs had anti-spike titers of about 100.

The company expects to have data from challenge studies in multiple animal models in the coming weeks, as well as preliminary Phase I data for INO-4800 next month. It plans to start a Phase II/III trial in July or August.

Inovio joins at least four other groups -- the University of Oxford and partner Vaccitech Ltd.; Sinovac Biotech Ltd. (NASDAQ:SVA); the University of Pittsburgh; and Moderna Inc. (NASDAQ:MRNA) -- to announce successful induction of anti-spike antibodies in mice.

Of the five teams, only Inovio, Oxford and Sinovac have reported antibody titers.

Moderna has not released detailed preclinical data from its candidate mRNA-1273, but the company announced Monday that the vaccine induced neutralizing antibodies in humans (see “What Moderna’s COVID-19 Vaccine Data Do Not Say”).

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers